Surgical results of pars plana vitrectomy combined with pars plana lensectomy with anterior capsule preservation, endophotocoagulation, and silicon oil tamponade for neovascular glaucoma

Nozomi Kinoshita
Ayumi Ota
Fumihiko Toyoda
Hiroko Yamagami
Akihiro Kakehashi
Department of Ophthalmology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

Purpose: To report on pars plana vitrectomy (PPV) combined with pars plana lensectomy (PPL) with a preserved anterior capsule, panretinal endophotocoagulation (EPC) throughout the pars plana, and silicon oil (SO) tamponade (PPV + PPL + EPC + SO tamponade) for neovascular glaucoma (NVG).

Methods: Thirteen eyes with NVG were treated. Ten eyes also underwent SO removal and intraocular lens (IOL) implantation (SO removal + IOL). Intraocular pressure (IOP), number of medications, and visual acuity were evaluated at the first visit, immediately before and 3 months after the procedure, 3 months after SO removal + IOL, and 1 year after the procedure.

Results: At the first visit, immediately before and 3 months after the procedure, 3 months after SO removal + IOL, and 1 year after the procedure, the IOPs were 29 ± 19, 23 ± 12, 13 ± 5, 17 ± 10, and 17 ± 6 mmHg; numbers of medications, 0.7 ± 1.4, 2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, and 1.6 ± 1.6; and best-corrected visual acuities converted to logarithm of the minimum angle of resolution (BCVA logMAR), 0.96 ± 0.96, 1.27 ± 0.80, 1.67 ± 0.91, 1.37 ± 0.89, and 1.90 ± 1.44, respectively. No severe hypotony or phthisis bulbi developed within 1 year after the procedure. The success rates (IOP ≤ 21 mmHg and sustained light perception) were 92.3% after 3 months and 69.2% after 1 year.

Conclusion: PPV + PPL + EPC + SO tamponade might have prevented acute increases of vascular endothelial growth factor and inflammatory cytokine production postoperatively and resulted in good vision in patients with NVG.

Keywords: pars plana vitrectomy, pars plana lensectomy, panretinal endophotocoagulation, silicon oil, neovascular glaucoma

Introduction
Neovascular glaucoma (NVG) develops in cases with extensive ischemic retinal changes, such as proliferative diabetic retinopathy (PDR) and central retinal vein occlusion (CRVO). Vascular endothelial growth factor (VEGF) and inflammatory cytokines from the ischemic retina are thought to cause NVG.1–3 VEGF and inflammatory cytokines from the ischemic retina migrate to the anterior segment and stimulate the neovascularization in the iris and the angle. When neovascular fibrous tissues occupy the trabecular meshwork, aqueous outflow is disturbed and NVG develops eventually.

NVG is generally difficult to treat. Prophylactic panretinal photocoagulation (PRP) prevents development of NVG4–6 and can be effective for early-stage NVG.7,8 Application of PRP induces regression of neovascularization in the angle, and aqueous outflow can be
PPV was to evaluate the results of this new surgical procedure, SO tamponade, for open-angle NVG. The aim of the current study was to determine the efficacy of PPV combined with pars plana lensectomy (PPL) with prophylactic endophotocoagulation (EPC) to treat NVG. However, we experienced some advanced cases that developed extensive fibrous membrane formation and worsening rubeosis. Therefore, we performed PPV with or without EPC to treat NVG. Incomplete vitrectomy and incomplete retinal photocoagulation to the peripheral pars plana seem to cause extensive fibrous membrane formation and worsening rubeosis. Therefore, we performed PPV combined with pars plana lensectomy (PPL) with preservation of the anterior capsule, EPC throughout the pars plana, and silicon oil (SO) tamponade (PPV + PPL + EPC + SO tamponade) to treat NVG. The aim of the current study was to evaluate the results of this new surgical procedure, PPV + PPL + EPC + SO tamponade, for open-angle NVG.

Patients and methods

Thirteen eyes of eleven cases with NVG were included from July 2004 to January 2007 and underwent PPV + PPL + EPC + SO tamponade. All eyes had undergone PRP previously and were diagnosed with open-angle NVG. Twelve eyes had a history of PDR and one eye had a history of CRVO; the mean patient age (mean ± standard deviation [SD]) was 57.9 ± 10.5 years. The male:female ratio was 9:2. Ten eyes of nine cases also underwent SO removal and IOL implantation (SO removal + IOL); the mean patient age was 59.3 ± 10.6 years. The male:female ratio was 7:2. The interval between SO tamponade and removal (mean ± SD) was 205 ± 91 days.

We performed PPV using a three-port technique in all patients. We performed PPL extraction in twelve phakic eyes using the Fragmatome (Alcon, Fort Worth, TX) and preserved the anterior lens capsule. The IOL was left in place in one pseudophakic eye. During PPV, posterior hyaloid separation was induced by suction using the vitreous cutter over the optic nerve head in a case without a posterior vitreous detachment. Fibrovascular membranes were removed using the total en-bloc excision technique. After PPV, EPC was performed throughout the pars plana, and the vitreous cavity was filled with SO.

We evaluated the intraocular pressure (IOP), the number of both antihypertensive eye drops and oral medications used, and the visual acuity (VA) using a Snellen chart at the time of the first visit, immediately before and 3 months after PPV + PPL + EPC + SO tamponade, another 3 months after SO removal + IOL, and 1 year after PPV + PPL + EPC + SO tamponade. The best-corrected decimal visual acuity was converted to the logarithm of the minimum angle of resolution (BCVA logMAR). Mermod et al defined therapeutic success as an IOP ≤21 mmHg and the presence of sustained light perception vision. Using these criteria, we calculated the success rates 3 months and 1 year after PPV + PPL + EPC + SO tamponade.

The Wilcoxon signed-rank test was used for statistical analysis in this study. The values are expressed as the mean ± SD. \( P < 0.05 \) was considered statistically significant.

Results

At the first visit, immediately before, and 3 months after PPV + PPL + EPC + SO tamponade, another 3 months after SO removal + IOL, and 1 year after PPV + PPL + EPC + SO tamponade, the mean IOPs (mean ± SD) were 29 ± 19, 23 ± 12, 13 ± 5, 17 ± 10, and 17 ± 6 mmHg (Figure 1); the numbers of medications (mean ± SD) were 0.7 ± 1.4, 2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, and 1.6 ± 1.6 (Figure 2); and the BCVA logMAR (mean ± SD) were 0.96 ± 0.96, 1.27 ± 0.80, 1.67 ± 0.91, 1.37 ± 0.89, and 1.90 ± 1.44, respectively. The IOP and the numbers of both antihypertensive eye drops and oral medications used for 3 months after PPV + PPL + EPC + SO tamponade decreased significantly compared with immediately before PPV + PPL + EPC + SO tamponade (\( P < 0.05 \)). However, the IOP and the numbers of both antihypertensive eye drops and oral medications used for another 3 months after SO removal + IOL and 1 year after PPV + PPL + EPC + SO tamponade did not decrease significantly compared with immediately before PPV + PPL + EPC + SO tamponade.

An IOP of 21 mmHg or lower was maintained in twelve of 13 eyes (92.3%) 3 months after PPV + PPL + EPC + SO tamponade, and an IOP of 21 mmHg or lower was maintained in eight of ten eyes (80%) 3 months after SO removal + IOL with or without medications. An IOP of 21 mmHg or lower was maintained in eleven of 13 eyes (84.6%) 1 year after PPV + PPL + EPC + SO tamponade with or without medications.
medications. No eyes developed severe hypotony or phthisis bulbi within 1 year after PPV + PPL + EPC + SO tamponade. Twelve of 13 eyes (92.3%) had light perception vision 3 months after PPV + PPL + EPC + SO tamponade. Six of ten eyes (60%) had improved VA 3 months after SO removal + IOL compared with 3 months after PPV + PPL + EPC + SO tamponade but this improvement was not statistically significant. Ten of 13 eyes (76.9%) had light perception vision 1 year after PPV + PPL + EPC + SO tamponade. The success rates of our procedure were 92.3% after 3 months and 69.2% after 1 year.

**Discussion**

The surgical results were considered successful because the IOP was well controlled with or without medications and the visual prognosis was good compared with previous reports of vitreous surgery for NVG. In our surgical technique, extensive PRP throughout the pars plana can be applied thanks to PPV + PPL. The major difference between our technique and previously reported vitreous surgery for NVG is that migration of VEGF and inflammatory cytokines from the posterior to the anterior segment is blocked as a result of preservation of the anterior lens capsule and SO tamponade. Rice et al reported a significant increase in the postoperative incidence of NVG in eyes undergoing combined lensectomy and vitrectomy compared with eyes in which the lens was not removed. Vitreous surgery without preservation of the anterior lens capsule and SO may induce acute production of VEGF and inflammatory cytokines because of retinal damage caused by PRP, which results in an acute immediate worsening of the NVG.

---

**Figure 1** The time course of IOP changes. At the first visit, immediately before and 3 months after PPV + PPL + EPC + SO tamponade, 3 months after SO removal + IOL, and 1 year after PPV + PPL + EPC + SO tamponade, the IOPs (mean ± SD) were 29 ± 19, 23 ± 12, 13 ± 5, 17 ± 10, and 17 ± 6 mmHg.

**Abbreviations:** mmHg, millimeters of mercury; IOP, intraocular pressure; SO, silicon oil; PPV, pars plana vitrectomy; PPL, pars plana lensectomy; EPC, endophotocoagulation; IOL, intraocular lens; SD, standard deviation

**Figure 2** The time course of changes in the numbers of antihypertensive eye drops and oral medications used. At the first visit, immediately before and 3 months after PPV + PPL + EPC + SO tamponade, 3 months after SO removal + IOL, and 1 year after PPV + PPL + EPC + SO tamponade, the numbers of medications used (mean ± SD) were 0.7 ± 1.4, 2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, and 1.6 ± 1.6.

**Abbreviations:** SO, silicon oil; PPV, pars plana vitrectomy; PPL, pars plana lensectomy; EPC, endophotocoagulation; IOL, intraocular lens; SD, standard deviation
Bartz-Schmidt et al\(^{22}\) reported on the results of lensectomy including removal of the lens capsule + PPV + EPC + SO tamponade to treat NVG. The differences compared with the current procedure were application of PRP to the ciliary body and the lens capsule was not preserved. Those authors applied PRP to the ciliary body to decrease the aqueous humor yield, but the incidence rate of severe hypotony or phthisis bulbi was high.\(^{22}\) We did not observe hypotony and phthisis bulbi in the current cases, because we did not apply EPC to the ciliary body. The current procedure differs from that of Bartz-Schmidt et al\(^{22}\) in that the ciliary body was intact, because the aim of the current procedure was to prevent migration of VEGF and inflammatory cytokines from the posterior to the anterior segment. Therefore, the current procedure might not be as effective for treating advanced angle-closure NVG, although this procedure might be considered to achieve regression of rubeosis. In cases of angle-closure NVG, trabeculectomy or cyclo-cryo/photocoagulation of the ciliary body should be performed after our procedure.

Trabeculectomy combined with injection of an anti-VEGF agent into the vitreous body was performed recently. However, the long-term effect of decreasing the IOP was insubstantial compared with trabeculectomy alone.\(^{27,28}\) The anti-VEGF agents caused temporary regression of the iris neovascularization, but the effect dissipated over time.

In conclusion, although NVG remains hard to treat, there may be a chance to preserve the visual function. It is important to prevent the transition from open-angle to angle-closure NVG by performing the procedure at the earliest possible opportunity. PPV + PPL + EPC + SO tamponade prevented blindness in our case series. We strongly recommend this procedure to treat NVG because it might effectively block VEGF and inflammatory cytokine production with preservation of the anterior lens capsule and SO.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


